EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study

Luca Mastorino iD, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni, Pietro Quaglino, Simone Ribero

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025-06 · 23 (6) · 693-699

DOI: 10.1111/ddg.15686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 26.04.2025. Verfasst von Luca Mastorino und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-23, Interleukin-17. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives De‐escalation strategies of biologics in psoriasis treatment are widespread in clinical practice. Dose spacing consists of de‐escalating the time range between biological drug injections. Patients and Methods Major objectives were: to describe trends in mean PASI, PASI 100, 90, and ≤ 1 from baseline to 12 months after dose spacing, provide drug survival analysis of dose‐spaced regimens, and concurrently describe phenotypic characteristics related to the selection of patient candidates for therapeutic dose spacing. A pre‐post analysis was made between mean PASI at dose spacing and baseline, and after 3, 6, 9, and 12 months following dose spacing.

Results

Of 1,144 patients treated with IL‐23 or IL‐17 inhibitors, 61 patients underwent dose spacing. They presented with lower mean baseline Body Mass Index (BMI) (p = 0.011) and PASI (Psoriasis Area Severity Index) (p = 0.044) and were more frequently bio‐experienced (p = 0.033). 12 months after dose spacing 42.9%, 85.7%, and 92.9% of observed patients achieved PASI 100, 90, and ≤1. There were no significant differences in mean PASI between dose spacing and subsequent time points. The dose spacing survival was 70% at 1 year.

Conclusions

Therapeutic modulation, such as dose spacing, is an effective strategy for most psoriasis patients, resulting in a clear or almost clear skin response that is maintained over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-23Interleukin-17HumansMaleFemalePilot ProjectsMiddle AgedAdultDrug Administration ScheduleDermatologic AgentsAgedDose-Response Relationship, DrugTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

IL‐17 inhibitorsIL‐23 inhibitorsPsoriasisbiologicsde‐escalationdose spacing

Substanzen

Interleukin-23Interleukin-17Dermatologic Agents

Autor:innen und Institutionen

  • Dermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.

ORCID-Profile: Luca Mastorino

Zitieren

APA

Mastorino, L., Dapavo, P., Ortoncelli, M., Bongiovanni, E., Quaglino, P., & Ribero, S. (2025). IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 23(6), 693-699. https://doi.org/10.1111/ddg.15686

Vancouver

Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Quaglino P, Ribero S. IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025;23(6):693-699. doi:10.1111/ddg.15686

BibTeX
@article{Mastorino2025,
  author = {Mastorino, Luca and Dapavo, Paolo and Ortoncelli, Michela and Bongiovanni, Eleonora and Quaglino, Pietro and Ribero, Simone},
  title = {IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2025},
  volume = {23},
  number = {6},
  pages = {693--699},
  doi = {10.1111/ddg.15686}
}
Kostenlos starten →